Localized Tongue Amyloidosis in a Patient with Neurofibromatosis Type II

被引：15
作者：
Andreadis D. [1 ]
Poulopoulos A. [1 ]
Papadopoulos P. [1 ]
Epivatianos A. [1 ]
机构：
[1] Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki
来源：
Head and Neck Pathology | 2011年 / 5卷 / 3期
关键词：
Neurofibromatosis type II; Oral amyloidosis;
D O I：
10.1007/s12105-011-0251-5
中图分类号：
学科分类号：
摘要：
Background: Localized Amyloidosis (AL) may rarely involve oral mucosa. This is the first known reported case describing the development of tongue AL in a 30-year-old patient with Neurofibromatosis (NF) type-2. Case: A female patient presented with a painless, well-circumscribed nodule of the tongue. Her medical history included NF type-2 with chromosome-22 abnormal karyotype (mosaicism), multiple intracranial and spinal meningiomas/schwannomas and unilateral blindness/deafness. The biopsy of the excised lesion of the tongue revealed subepithelial accumulation of an amorphous, nodular, fibrillar material positive for Congo red. Blood examination showed increased Thyroxine-T4 due to thyroid multinodular colloid goiter, but excluded any other hematological/immunological disorder or organ dysfunction. No recurrence was observed after a six-month follow-up. Conclusion: This case highlights the possibility of oral manifestations as the only sign of AL and reveals the unexpected co-existence of AL and NF 2, for the first time. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码：302 / 305
页数：3
相关论文
共 39 条
[21]  
Khan M.F., Falk R.H., Amyloidosis, Postgrad Med J, 77, 913, pp. 686-693, (2001)
[22]  
Steciuk A., Dompmartin A., Troussard X., Et al., Cutaneous amyloidosis and possible association with systemic amyloidosis, Int J Dermatol, 41, 3, pp. 127-134, (2002)
[23]  
van der Waal R.I., van de Scheur M.R., Huijgens P.C., Et al., Amyloidosis of the tongue as a paraneoplastic marker of plasma cell dyscrasia, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 94, 4, pp. 444-447, (2002)
[24]  
Sanchorawala V., Blanchard E., Seldin D.C., Et al., AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes, Am J Hematol, 81, 9, pp. 692-695, (2006)
[25]  
Falk R.H., Skinner M., The systemic amyloidoses: an overview, Adv Intern Med, 45, pp. 107-137, (2000)
[26]  
Rivera R.J., Vicenty S., Cardiac manifestations of amyloid disease, Bol Asoc Med P R, 100, 4, pp. 60-70, (2008)
[27]  
Nishi S., Alchi B., Imai N., New advances in renal amyloidosis, Clin Exp Nephrol, 12, 2, pp. 93-101, (2008)
[28]  
Petre S., Shah I.A., Gilani N., Review article: gastrointestinal amyloidosis-clinical features, diagnosis and therapy, Aliment Pharmacol Ther, 27, 11, pp. 1006-1016, (2008)
[29]  
Simmons Z., Specht C.S., The neuromuscular manifestations of amyloidosis, J Clin Neuromuscul Dis, 11, 3, pp. 145-157, (2010)
[30]  
Kerner M.M., Wang M.B., Angier G., Et al., Amyloidosis of the head and neck. A clinicopathologic study of the UCLA experience, 1955-1991, Arch Otolaryngol Head Neck Surg, 121, 7, pp. 778-782, (1995)
1234